{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:12:30Z","timestamp":1790611950060,"version":"4.1.0"},"reference-count":96,"publisher":"American Society of Hematology","issue":"7","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,4,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Standardization of the detection and quantification of leukocyte differentiation markers by the EuroFlow Consortium has led to a major step forward in the integration of flow cytometry into classification of leukemia and lymphoma. In our opinion, this now enables introduction of markers for more dynamic parameters, such as proliferative and (anti)apoptotic markers, which have proven their value in the field of histopathology in the diagnostic process of solid tumors and lymphoma. Although use of proliferative and (anti)apoptotic markers as objective parameters in the diagnostic process of myeloid malignancies was studied in the past decades, this did not result in the incorporation of these biomarkers into clinical diagnosis. This review addresses the potential of these markers for implementation in the current, state-of-the-art multiparameter analysis of myeloid malignancies. The reviewed studies clearly recognize the importance of proliferation and apoptotic mechanisms in the pathogenesis of bone marrow (BM) malignancies. The literature is, however, contradictory on the role of these processes in myelodysplastic syndrome (MDS), MDS\/myeloproliferative neoplasms, and acute myeloid leukemia. Furthermore, several studies underline the need for the analysis of the proliferative and apoptotic rates in subsets of hematopoietic BM cell lineages and argue that these results can have diagnostic and prognostic value in patients with myeloid malignancies. Recent developments in multiparameter flow cytometry now allow quantification of proliferative and (anti)apoptotic indicators in myeloid cells during their different maturation stages of separate hematopoietic cell lineages. This will lead to a better understanding of the biology and pathogenesis of these malignancies.<\/jats:p>","DOI":"10.1182\/bloodadvances.2020004094","type":"journal-article","created":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T23:25:13Z","timestamp":1618356313000},"page":"2040-2052","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":13,"title":["The potential of proliferative and apoptotic parameters in clinical flow cytometry of myeloid malignancies"],"prefix":"10.1182","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4694-8484","authenticated-orcid":false,"given":"Stefan G. C.","family":"Mestrum","sequence":"first","affiliation":[{"name":"Department of Clinical Chemistry and Hematology, Zuyderland Medical Centre, Sittard-Geleen, The Netherlands;"},{"name":"Department of Molecular Cell Biology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton H. N.","family":"Hopman","sequence":"additional","affiliation":[{"name":"Department of Molecular Cell Biology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frans C. S.","family":"Ramaekers","sequence":"additional","affiliation":[{"name":"Department of Molecular Cell Biology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands; and"},{"name":"Nordic-MUbio, Susteren, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5186-5600","authenticated-orcid":false,"given":"Math P. G.","family":"Leers","sequence":"additional","affiliation":[{"name":"Department of Clinical Chemistry and Hematology, Zuyderland Medical Centre, Sittard-Geleen, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2021,4,13]]},"reference":[{"issue":"12","key":"2021041315321654900_B1","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/blood-2014-10-607341","article-title":"An international consortium proposal of uniform response criteria for myelodysplastic\/myeloproliferative neoplasms (MDS\/MPN) in adults","volume":"125","author":"Savona","year":"2015","journal-title":"Blood"},{"issue":"1","key":"2021041315321654900_B2","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3892\/ol.2017.6106","article-title":"Pediatric haematopoiesis and related malignancies","volume":"14","author":"Jin","year":"2017","journal-title":"Oncol Lett"},{"issue":"5405","key":"2021041315321654900_B3","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature"},{"issue":"10","key":"2021041315321654900_B4","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","article-title":"The molecular biology of chronic myeloid leukemia","volume":"96","author":"Deininger","year":"2000","journal-title":"Blood"},{"issue":"12","key":"2021041315321654900_B5","doi-asserted-by":"crossref","first-page":"913","DOI":"10.7326\/0003-4819-145-12-200612190-00008","article-title":"New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance","volume":"145","author":"Kantarjian","year":"2006","journal-title":"Ann Intern Med"},{"issue":"7037","key":"2021041315321654900_B6","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"issue":"17","key":"2021041315321654900_B7","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N Engl J Med"},{"issue":"4","key":"2021041315321654900_B8","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"issue":"9","key":"2021041315321654900_B9","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.3324\/haematol.2014.114660","article-title":"An international MDS\/MPN working group\u2019s perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic\/myeloproliferative neoplasms","volume":"100","author":"Mughal","year":"2015","journal-title":"Haematologica"},{"issue":"4","key":"2021041315321654900_B10","doi-asserted-by":"crossref","first-page":"568","DOI":"10.3324\/haematol.2012.071449","article-title":"Reproducibility of the World Health Organization 2008 criteria for myelodysplastic syndromes","volume":"98","author":"Senent","year":"2013","journal-title":"Haematologica"},{"issue":"1","key":"2021041315321654900_B11","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1182\/blood-2002-09-2768","article-title":"Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation","volume":"102","author":"Wells","year":"2003","journal-title":"Blood"},{"issue":"3","key":"2021041315321654900_B12","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1182\/blood-2005-12-4916","article-title":"Diagnostic application of flow cytometric characteristics of CD34+ cells in low-grade myelodysplastic syndromes","volume":"108","author":"Ogata","year":"2006","journal-title":"Blood"},{"issue":"20","key":"2021041315321654900_B13","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"5","key":"2021041315321654900_B14","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood"},{"key":"2021041315321654900_B15","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1002\/cyto.b.20363","article-title":"2006 Bethesda International Consensus recommendations on the immunophenotypic analysis of hematolymphoid neoplasia by flow cytometry: optimal reagents and reporting for the flow cytometric diagnosis of hematopoietic neoplasia","volume":"72","author":"Wood","year":"2007","journal-title":"Cytometry B Clin Cytom"},{"issue":"10","key":"2021041315321654900_B16","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1182\/blood-2018-10-844670","article-title":"MDS overlap disorders and diagnostic boundaries","volume":"133","author":"Tanaka","year":"2019","journal-title":"Blood"},{"issue":"9","key":"2021041315321654900_B17","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1038\/leu.2012.122","article-title":"EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols","volume":"26","author":"Kalina","year":"2012","journal-title":"Leukemia"},{"issue":"4","key":"2021041315321654900_B18","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1038\/leu.2017.313","article-title":"Automated database-guided expert-supervised orientation for immunophenotypic diagnosis and classification of acute leukemia","volume":"32","author":"Lhermitte","year":"2018","journal-title":"Leukemia"},{"issue":"9","key":"2021041315321654900_B19","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1038\/leu.2012.120","article-title":"EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes","volume":"26","author":"van Dongen","year":"2012","journal-title":"Leukemia"},{"issue":"5","key":"2021041315321654900_B20","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"issue":"6","key":"2021041315321654900_B21","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1038\/bjc.2014.402","article-title":"Tumour cell proliferation (Ki-67) in non-small cell lung cancer: a critical reappraisal of its prognostic role","volume":"111","author":"Warth","year":"2014","journal-title":"Br J Cancer"},{"issue":"7","key":"2021041315321654900_B22","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1038\/bjc.2013.533","article-title":"The prognostic impact of a combined carbonic anhydrase IX and Ki67 signature in oral squamous cell carcinoma","volume":"109","author":"Klimowicz","year":"2013","journal-title":"Br J Cancer"},{"issue":"4","key":"2021041315321654900_B23","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1002\/(SICI)1097-0215(19960822)69:4<324::AID-IJC15>3.0.CO;2-5","article-title":"Bcl-2 expression and prognosis in squamous-cell carcinomas of the esophagus","volume":"69","author":"Sarbia","year":"1996","journal-title":"Int J Cancer"},{"issue":"1","key":"2021041315321654900_B24","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1007\/s12032-014-0416-7","article-title":"Expression of caspase-3 predicts prognosis in advanced noncardia gastric cancer","volume":"32","author":"Amptoulach","year":"2015","journal-title":"Med Oncol"},{"issue":"1","key":"2021041315321654900_B25","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1182\/blood.V87.1.265.265","article-title":"Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin\u2019s lymphoma. Groupe d\u2019Etude des Lymphomes de l\u2019Adulte (GELA)","volume":"87","author":"Hermine","year":"1996","journal-title":"Blood"},{"issue":"4","key":"2021041315321654900_B26","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/ejh.12578","article-title":"Molecular diagnostics of myeloproliferative neoplasms","volume":"95","author":"Langabeer","year":"2015","journal-title":"Eur J Haematol"},{"issue":"8","key":"2021041315321654900_B27","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1080\/10428194.2016.1265116","article-title":"Current trends in molecular diagnostics of chronic myeloid leukemia","volume":"58","author":"Vinhas","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"2021041315321654900_B28","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/1471-2407-14-153","article-title":"Ki-67 is a valuable prognostic predictor of lymphoma but its utility varies in lymphoma subtypes: evidence from a systematic meta-analysis","volume":"14","author":"He","year":"2014","journal-title":"BMC Cancer"},{"issue":"12","key":"2021041315321654900_B29","doi-asserted-by":"crossref","first-page":"3932","DOI":"10.1182\/blood.V96.12.3932","article-title":"The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS","volume":"96","author":"Parker","year":"2000","journal-title":"Blood"},{"issue":"8","key":"2021041315321654900_B30","doi-asserted-by":"crossref","first-page":"e44321","DOI":"10.1371\/journal.pone.0044321","article-title":"The proliferation index of specific bone marrow cell compartments from myelodysplastic syndromes is associated with the diagnostic and patient outcome","volume":"7","author":"Matarraz","year":"2012","journal-title":"PLoS One"},{"issue":"11","key":"2021041315321654900_B31","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1002\/cyto.a.23564","article-title":"Determination of the proliferative fractions in differentiating hematopoietic cell lineages of normal bone marrow","volume":"93","author":"Nies","year":"2018","journal-title":"Cytometry A"},{"key":"2021041315321654900_B32","article-title":"Proliferative activity is disturbed in myeloproliferative neoplasms (MPN), myelodysplastic syndrome (MDS), and MDS\/MPN diseases. Differences between MDS and MDS\/MPN [published online ahead of print 28 August 2020]","author":"Mestrum","journal-title":"Cytometry B Clin Cytom"},{"issue":"10","key":"2021041315321654900_B33","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1136\/jcp.41.10.1120","article-title":"Assessment of DNA content and cell cycle distribution of erythroid and myeloid cells from bone marrow","volume":"41","author":"Hodgetts","year":"1988","journal-title":"J Clin Pathol"},{"issue":"1-2","key":"2021041315321654900_B34","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0022-1759(99)00116-7","article-title":"A novel cell permeant and far red-fluorescing DNA probe, DRAQ5, for blood cell discrimination by flow cytometry","volume":"229","author":"Smith","year":"1999","journal-title":"J Immunol Methods"},{"issue":"4","key":"2021041315321654900_B35","first-page":"427","article-title":"Cell-cycle analysis using a monoclonal antibody to BrdUrd","volume":"17","author":"Dean","year":"1984","journal-title":"Cell Tissue Kinet"},{"issue":"4571","key":"2021041315321654900_B36","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1126\/science.7123245","article-title":"Monoclonal antibody to 5-bromo- and 5-iododeoxyuridine: A new reagent for detection of DNA replication","volume":"218","author":"Gratzner","year":"1982","journal-title":"Science"},{"issue":"6","key":"2021041315321654900_B37","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1046\/j.1440-1711.1999.00864.x","article-title":"Divided we stand: tracking cell proliferation with carboxyfluorescein diacetate succinimidyl ester","volume":"77","author":"Lyons","year":"1999","journal-title":"Immunol Cell Biol"},{"issue":"1","key":"2021041315321654900_B38","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/0022-1759(94)90236-4","article-title":"Determination of lymphocyte division by flow cytometry","volume":"171","author":"Lyons","year":"1994","journal-title":"J Immunol Methods"},{"issue":"4","key":"2021041315321654900_B39","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.4049\/jimmunol.133.4.1710","article-title":"Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67","volume":"133","author":"Gerdes","year":"1984","journal-title":"J Immunol"},{"issue":"1","key":"2021041315321654900_B40","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/0014-4827(86)90520-3","article-title":"Expression of proliferating cell nuclear antigen (PCNA)\/cyclin during the cell cycle","volume":"166","author":"Kurki","year":"1986","journal-title":"Exp Cell Res"},{"issue":"5","key":"2021041315321654900_B41","doi-asserted-by":"crossref","first-page":"365","DOI":"10.2174\/1568009054629654","article-title":"The MCM complex: its role in DNA replication and implications for cancer therapy","volume":"5","author":"Lei","year":"2005","journal-title":"Curr Cancer Drug Targets"},{"issue":"3","key":"2021041315321654900_B42","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1083\/jcb.119.3.493","article-title":"Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation","volume":"119","author":"Gavrieli","year":"1992","journal-title":"J Cell Biol"},{"issue":"2","key":"2021041315321654900_B43","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1002\/(SICI)1097-0320(19960601)24:2<131::AID-CYTO5>3.0.CO;2-M","article-title":"A novel assay to measure loss of plasma membrane asymmetry during apoptosis of adherent cells in culture","volume":"24","author":"van Engeland","year":"1996","journal-title":"Cytometry"},{"issue":"1","key":"2021041315321654900_B44","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0165-0270(98)00147-2","article-title":"Annexin V binding assay as a tool to measure apoptosis in differentiated neuronal cells","volume":"86","author":"Schutte","year":"1998","journal-title":"J Neurosci Methods"},{"issue":"4","key":"2021041315321654900_B45","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/0092-8674(93)90508-N","article-title":"Bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death","volume":"74","author":"Boise","year":"1993","journal-title":"Cell"},{"issue":"4","key":"2021041315321654900_B46","first-page":"665","article-title":"Bcl-w, a novel member of the bcl-2 family, promotes cell survival","volume":"13","author":"Gibson","year":"1996","journal-title":"Oncogene"},{"issue":"7","key":"2021041315321654900_B47","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/0092-8674(91)90007-L","article-title":"Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death","volume":"65","author":"Henderson","year":"1991","journal-title":"Cell"},{"issue":"4","key":"2021041315321654900_B48","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/0092-8674(93)90509-O","article-title":"Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death","volume":"74","author":"Oltvai","year":"1993","journal-title":"Cell"},{"issue":"8","key":"2021041315321654900_B49","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nm0897-917","article-title":"A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma","volume":"3","author":"Ambrosini","year":"1997","journal-title":"Nat Med"},{"issue":"4","key":"2021041315321654900_B50","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/0092-8674(93)90486-A","article-title":"Induction of apoptosis in fibroblasts by IL-1 beta-converting enzyme, a mammalian homolog of the C. elegans cell death gene ced-3","volume":"75","author":"Miura","year":"1993","journal-title":"Cell"},{"issue":"6333","key":"2021041315321654900_B51","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/352345a0","article-title":"Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6","volume":"352","author":"Yonish-Rouach","year":"1991","journal-title":"Nature"},{"issue":"4","key":"2021041315321654900_B52","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1080\/01926230701320337","article-title":"Apoptosis: a review of programmed cell death","volume":"35","author":"Elmore","year":"2007","journal-title":"Toxicol Pathol"},{"issue":"3","key":"2021041315321654900_B53","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1084\/jem.187.3.415","article-title":"Disruption of fas receptor signaling by nitric oxide in eosinophils","volume":"187","author":"Hebestreit","year":"1998","journal-title":"J Exp Med"},{"key":"2021041315321654900_B54","first-page":"26834","article-title":"Mechanisms for mTORC1 activation and synergistic induction of apoptosis by ruxolitinib and BH3 mimetics or autophagy inhibitors in JAK2-V617F-expressing leukemic cells including newly established PVTL-2","volume-title":"Oncotarget","author":"Ishida","year":"2018"},{"key":"2021041315321654900_B55","author":"Hui","year":"2016"},{"issue":"8","key":"2021041315321654900_B56","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1182\/blood.V83.8.2038.2038","article-title":"Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia","volume":"83","author":"Bedi","year":"1994","journal-title":"Blood"},{"issue":"2","key":"2021041315321654900_B57","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1136\/jclinpath-2015-203177","article-title":"Megakaryocytic hyperplasia in myeloproliferative neoplasms is driven by disordered proliferative, apoptotic and epigenetic mechanisms","volume":"69","author":"Malherbe","year":"2016","journal-title":"J Clin Pathol"},{"issue":"6","key":"2021041315321654900_B58","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/S0145-2126(01)00170-9","article-title":"Proliferation and apoptosis in acute and chronic leukemias and myelodysplastic syndrome","volume":"26","author":"Lin","year":"2002","journal-title":"Leuk Res"},{"issue":"1","key":"2021041315321654900_B59","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/BF01606429","article-title":"Myelodysplastic syndromes: immunohistochemical and morphometric evaluation of proliferative activity in erythropoiesis and endoreduplicative capacity of megakaryocytes","volume":"423","author":"Thiele","year":"1993","journal-title":"Virchows Arch A Pathol Anat Histopathol"},{"issue":"1","key":"2021041315321654900_B60","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/0165-4608(92)90041-6","article-title":"Cell-cycle progression rates and sister chromatid exchange frequencies in the bone marrow of patients with myelodysplastic syndrome and acute myeloid leukemia","volume":"62","author":"Jones","year":"1992","journal-title":"Cancer Genet Cytogenet"},{"issue":"11","key":"2021041315321654900_B61","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1038\/labinvest.2014.110","article-title":"CXCL12+ stromal cells as bone marrow niche for CD34+ hematopoietic cells and their association with disease progression in myelodysplastic syndromes","volume":"94","author":"Abe-Suzuki","year":"2014","journal-title":"Lab Invest"},{"issue":"2","key":"2021041315321654900_B62","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3816\/CLK.2008.n.014","article-title":"Increased apoptosis as a mechanism of ineffective erythropoiesis in myelodysplastic syndromes","volume":"2","author":"Invernizzi","year":"2008","journal-title":"Clin Leuk"},{"issue":"4","key":"2021041315321654900_B63","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1046\/j.1365-2141.1998.01114.x","article-title":"\u201cLow-risk\u201d myelodysplastic syndrome is associated with excessive apoptosis and an increased ratio of pro- versus anti-apoptotic bcl-2-related proteins","volume":"103","author":"Parker","year":"1998","journal-title":"Br J Haematol"},{"key":"2021041315321654900_B64","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3389\/fonc.2016.00151","article-title":"Unraveling the pathogenesis of MDS: the NLRP3 inflammasome and pyroptosis drive the MDS phenotype","volume":"6","author":"Sallman","year":"2016","journal-title":"Front Oncol"},{"issue":"8","key":"2021041315321654900_B65","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1038\/s41591-018-0082-y","article-title":"DPP8\/DPP9 inhibitor-induced pyroptosis for treatment of acute myeloid leukemia","volume":"24","author":"Johnson","year":"2018","journal-title":"Nat Med"},{"issue":"6","key":"2021041315321654900_B66","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/j.immuni.2012.08.027","article-title":"NLRP1 inflammasome activation induces pyroptosis of hematopoietic progenitor cells","volume":"37","author":"Masters","year":"2012","journal-title":"Immunity"},{"issue":"1","key":"2021041315321654900_B67","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0609.1986.tb02643.x","article-title":"Adult acute non-lymphoblastic leukaemia: reliability and prognostic significance of pretreatment bone marrow S-phase size determined by flow cytofluorometry","volume":"36","author":"Riccardi","year":"1986","journal-title":"Scand J Haematol"},{"issue":"7","key":"2021041315321654900_B68","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/0277-5379(91)90139-5","article-title":"Cell kinetics with in vivo bromodeoxyuridine and flow cytometry: clinical significance in acute non-lymphoblastic leukaemia","volume":"27","author":"Riccardi","year":"1991","journal-title":"Eur J Cancer"},{"issue":"5","key":"2021041315321654900_B69","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/BF01738470","article-title":"Proliferation patterns in acute myeloid leukemia: leukemic clonogenic growth and in vivo cell cycle kinetics","volume":"66","author":"Brons","year":"1993","journal-title":"Ann Hematol"},{"issue":"8-9","key":"2021041315321654900_B70","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1007\/s10735-004-2341-0","article-title":"Expression of the proliferation-associated nuclear protein MIB-1 and its relationship with microvascular density in bone marrow biopsies of patients with myelodysplastic syndromes","volume":"35","author":"Alexandrakis","year":"2004","journal-title":"J Mol Histol"},{"issue":"1","key":"2021041315321654900_B71","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4081\/923","article-title":"The assessment of proliferating cell nuclear antigen immunostaining in myelodysplastic syndromes and its prognostic significance","volume":"49","author":"Alexandrakis","year":"2005","journal-title":"Eur J Histochem"},{"issue":"3","key":"2021041315321654900_B72","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/BF02982044","article-title":"Biological significance of proliferation, apoptosis, cytokines, and monocyte\/macrophage cells in bone marrow biopsies of 145 patients with myelodysplastic syndrome","volume":"75","author":"Allampallam","year":"2002","journal-title":"Int J Hematol"},{"issue":"9","key":"2021041315321654900_B73","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0145-2126(98)00051-4","article-title":"Bcl-2 expression by myeloid precursors in myelodysplastic syndromes: relation to disease progression","volume":"22","author":"Davis","year":"1998","journal-title":"Leuk Res"},{"issue":"6","key":"2021041315321654900_B74","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1182\/blood-2002-06-1714","article-title":"Amount of spontaneous apoptosis detected by Bax\/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML)","volume":"101","author":"Del Poeta","year":"2003","journal-title":"Blood"},{"issue":"6","key":"2021041315321654900_B75","doi-asserted-by":"crossref","first-page":"666","DOI":"10.4149\/neo_2013_085","article-title":"Overexpression of Bcl2 protein predicts chemoresistance in acute myeloid leukemia: its correlation with FLT3","volume":"60","author":"Mehta","year":"2013","journal-title":"Neoplasma"},{"issue":"11","key":"2021041315321654900_B76","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1080\/10428190412331283251","article-title":"Survivin expression in acute leukemias and myelodysplastic syndromes","volume":"45","author":"Invernizzi","year":"2004","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"2021041315321654900_B77","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/j.0902-4441.2006.t01-1-EJH2588.x","article-title":"Survivin expression, apoptosis and proliferation in chronic myelomonocytic leukemia","volume":"76","author":"Invernizzi","year":"2006","journal-title":"Eur J Haematol"},{"issue":"6","key":"2021041315321654900_B78","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1002\/ijc.21995","article-title":"In vivo expression of survivin and its splice variant survivin-2B: impact on clinical outcome in acute myeloid leukemia","volume":"119","author":"Wagner","year":"2006","journal-title":"Int J Cancer"},{"issue":"1","key":"2021041315321654900_B79","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/sj.leu.2401233","article-title":"Fas ligand expression in the bone marrow in myelodysplastic syndromes correlates with FAB subtype and anemia, and predicts survival","volume":"13","author":"Gupta","year":"1999","journal-title":"Leukemia"},{"issue":"3","key":"2021041315321654900_B80","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1046\/j.1365-2141.2000.02228.x","article-title":"Evaluation of apoptosis as a prognostic factor in myelodysplastic syndromes","volume":"110","author":"Shimazaki","year":"2000","journal-title":"Br J Haematol"},{"issue":"8","key":"2021041315321654900_B81","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1080\/1042819031000083037","article-title":"Imbalance between apoptosis and telomerase activity in myelodysplastic syndromes: possible role in ineffective hemopoiesis","volume":"44","author":"Ohshima","year":"2003","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"2021041315321654900_B82","doi-asserted-by":"crossref","first-page":"861","DOI":"10.17219\/acem\/93849","article-title":"Significance of apoptosis and autophagy of leukemic blasts for the outcomes of acute myeloid leukemia patients","volume":"28","author":"Dere\u0144-Wagemann","year":"2019","journal-title":"Adv Clin Exp Med"},{"key":"2021041315321654900_B83","author":"Kadia","year":"2019"},{"issue":"11","key":"2021041315321654900_B84","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1080\/10428194.2020.1775214","article-title":"Venetoclax and hypomethylating agent therapy in high risk myelodysplastic syndromes: a retrospective evaluation of a real-world experience","volume":"61","author":"Azizi","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"13","key":"2021041315321654900_B85","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1182\/bloodadvances.2020001482","article-title":"Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure","volume":"4","author":"Ball","year":"2020","journal-title":"Blood Adv"},{"issue":"5","key":"2021041315321654900_B86","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/ejh.13218","article-title":"Durable remissions with venetoclax monotherapy in secondary AML refractory to hypomethylating agents and high expression of BCL-2 and\/or BIM","volume":"102","author":"Huemer","year":"2019","journal-title":"Eur J Haematol"},{"issue":"43","key":"2021041315321654900_B87","doi-asserted-by":"crossref","first-page":"73483","DOI":"10.18632\/oncotarget.19008","article-title":"Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions","volume":"8","author":"Valent","year":"2017","journal-title":"Oncotarget"},{"issue":"2","key":"2021041315321654900_B88","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/cyto.a.22581","article-title":"Quality assessment program for EuroFlow protocols: Summary results of four-year (2010-2013) quality assurance rounds","volume":"87","author":"Kalina","year":"2015","journal-title":"Cytometry A"},{"issue":"7","key":"2021041315321654900_B89","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1136\/jcp.54.7.508","article-title":"UK NEQAS for leucocyte immunophenotyping: the first 10 years","volume":"54","author":"Reilly","year":"2001","journal-title":"J Clin Pathol"},{"issue":"10","key":"2021041315321654900_B90","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1038\/leu.2017.29","article-title":"Next generation flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma","volume":"31","author":"Flores-Montero","year":"2017","journal-title":"Leukemia"},{"issue":"2","key":"2021041315321654900_B91","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/CCO.0000000000000613","article-title":"Single-cell sequencing in hematology","volume":"32","author":"Brierley","year":"2020","journal-title":"Curr Opin Oncol"},{"key":"2021041315321654900_B92","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/978-1-4939-7142-8_5","article-title":"Single-cell mass cytometry of acute myeloid leukemia and leukemia stem\/progenitor cells","volume":"1633","author":"Zeng","year":"2017","journal-title":"Methods Mol Biol"},{"issue":"11","key":"2021041315321654900_B93","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41408-018-0148-6","article-title":"Challenges in the introduction of next-generation sequencing (NGS) for diagnostics of myeloid malignancies into clinical routine use","volume":"8","author":"Bacher","year":"2018","journal-title":"Blood Cancer J"},{"issue":"1","key":"2021041315321654900_B94","doi-asserted-by":"crossref","first-page":"e0227986","DOI":"10.1371\/journal.pone.0227986","article-title":"Assessment of the clinical utility of four NGS panels in myeloid malignancies. Suggestions for NGS panel choice or design","volume":"15","author":"Aguilera-Diaz","year":"2020","journal-title":"PLoS One"},{"issue":"2","key":"2021041315321654900_B95","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1097\/CCO.0000000000000607","article-title":"Computational analysis of flow cytometry data in hematological malignancies: future clinical practice?","volume":"32","author":"Duetz","year":"2020","journal-title":"Curr Opin Oncol"},{"issue":"14","key":"2021041315321654900_B96","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1182\/bloodadvances.2020002230","article-title":"Artificial intelligence-based morphological fingerprinting of megakaryocytes: a new tool for assessing disease in MPN patients","volume":"4","author":"Sirinukunwattana","year":"2020","journal-title":"Blood Adv"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/7\/2040\/1804901\/advancesadv2020004094.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/7\/2040\/1804901\/advancesadv2020004094.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T22:09:19Z","timestamp":1698876559000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/5\/7\/2040\/475703\/The-potential-of-proliferative-and-apoptotic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,13]]},"references-count":96,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,4,13]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2020004094","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,13]]}}}